Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
about
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsPlasma membrane transporters in modern liver pharmacologyCell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirinCoronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeuticsHost-based ribavirin resistance influences hepatitis C virus replication and treatment response.Antiviral activity and possible mechanism of action of constituents identified in Paeonia lactiflora root toward human rhinoviruses.Isolation of fidelity variants of RNA viruses and characterization of virus mutation frequency.Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization.Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN ProductionRibavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsHCV infection selectively impairs type I but not type III IFN signaling.Role of ribavirin in HCV treatment response: now and in the future.Plaques Formed by Mutagenized Viral Populations Have Elevated Coinfection Frequencies.Basic answers to complicated questions for the course of chronic hepatitis C treatment.Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.Selection of hepatitis C virus resistant to ribavirin.Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against Ischemia-Reperfusion Injury?Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats.Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Quasispecies and Drug Resistance
P2860
Q26777408-C16DEDFA-D409-43F9-9100-D947A356E611Q26829263-865E8538-A8CD-4A84-A3E6-305CBB3B22A7Q28474617-1CE71055-2A9E-4C76-B7BB-BB80D3D1B6A9Q28535361-86A210C0-A05A-45BB-B175-B734D5F32DE2Q35077712-DCCA917E-2FFB-456B-8374-347C4B56FA11Q35362286-CC27DBAA-D040-4FE1-BB07-F12AD2ACA74AQ35391721-8DBAF9B4-A51D-49EA-9990-343972B5B405Q35564506-070F8CBB-0647-462E-A739-C4D2F4BE97E1Q35692423-B598659C-E4DD-43F0-A4DC-9F19DC3CF5E4Q35746343-1EC2EFC6-A00C-4503-8721-EA42C53C0540Q36399860-0B1CDB77-7678-43AC-B629-B0617B9EB269Q37415444-98F01C8B-89F3-45EF-9931-203A6AEB4315Q37693948-4AEBCAB9-C2EF-4398-891F-9769791DF959Q37700069-E1E6F439-C0E7-4B22-BE03-906A2CDD91D9Q38014499-9A6D3654-8014-4E21-8F9E-9B2D648EDD9DQ38262107-071C11C3-CAF9-4132-9C21-BF35593B13FDQ38269623-7883F5CA-ACB2-44F7-A4CF-B9ED119E23D1Q38526404-4D75131A-C5D7-488D-9F62-B95B9B6239D0Q38665457-9E120EC6-183A-4C7C-AD9D-5E87153EEA8EQ40755393-D857D864-86A7-42DE-ADE3-057F74CF5983Q43048075-19A6D436-F27E-48FF-82C1-EF35E7EDB426Q43280688-71503398-917F-446F-B62E-967AB4416693Q56957250-CB42B965-FE3C-4FCC-B37C-BC1FA7A1D004
P2860
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@ast
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@en
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@nl
type
label
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@ast
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@en
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@nl
prefLabel
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@ast
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@en
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@nl
P2860
P356
P1433
P1476
Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance
@en
P2093
Julie K Pfeiffer
Kristie D Ibarra
P2860
P304
P356
10.1128/JVI.02280-08
P577
2009-05-01T00:00:00Z